Bisperoxovanadium, a phospho‐tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotypeLaura Castaldi, Marina Bouché, Carlo Serra et al.|The FASEB Journal|2007Cited by 19
Clinical Synthesis Conference. Hormone replacement therapy (Reprinted from The Lancet, vol 354, pg 152-155, 1999)Claire Grant, Hrt Csp., S. von Kleist et al.|Oxford University Research Archive (ORA) (University of Oxford)|2000Cited by 1